Dr. Milo Frattini | Molecular Biology | Best Researcher Award

Head of Biologists, quality and research of ICP at ICP EOC, Switzerland.

Dr. Milo Frattini is a distinguished molecular pathologist with over two decades of experience in translational cancer research. He currently serves as the Head of the Laboratory of Molecular Pathology at the Institute of Pathology, Ente Ospedaliero Cantonale, in Locarno, Switzerland. An Italian national, Dr. Frattini completed his early studies in Milan and went on to obtain a Ph.D. in Experimental Medicine and Oncology from the University of Insubria. His scientific journey reflects a strong commitment to oncology, molecular diagnostics, and quality assurance in clinical pathology. Dr. Frattini has authored over 100 peer-reviewed publications and several book chapters, and he plays a prominent role in editorial boards, including BMC Cancer and the Journal of Clinical Medicine. He is also a member of key professional societies such as the Swiss Society of Pathology and SAKK groups for gastrointestinal and lung cancer. His research significantly contributes to precision medicine and cancer care.

Professional Profile

Scopus

Orcid

Sutability For Best Researcher Award – Dr. Milo Frattini

Dr. Milo Frattini is an exceptionally strong candidate for the Best Researcher Award based on his extensive contributions to molecular oncology, translational cancer research, and diagnostic innovation. With over 20 years of impactful research, he has established himself as a scientific leader in integrating molecular diagnostics into routine cancer care. His sustained publication record (100+ peer-reviewed papers), leadership in clinical laboratory management, editorial contributions, and collaborative role in national cancer groups position him as a cornerstone of precision oncology in Switzerland and beyond.

🎓 Education 

Dr. Milo Frattini’s academic foundation began at the Scientific Lyceum of Milan, where he received a strong grounding in science. He pursued his undergraduate degree in Biology at the Università degli Studi of Milan, graduating in 1998 with the highest distinction (110/110 cum laude). His thesis investigated calcium-dependent protein kinases in rice, reflecting his early interest in molecular biology. Building upon this foundation, Dr. Frattini later transitioned his focus toward human health and cancer research. In 2014, he earned a Ph.D. in Experimental Medicine and Oncology from the University of Insubria in Varese, Italy. His doctoral thesis explored the molecular characteristics of small bowel adenocarcinoma, aiming to identify novel therapeutic targets. His educational trajectory demonstrates a unique evolution from plant molecular biology to clinical oncology, establishing the multidisciplinary expertise that underpins his current contributions to molecular pathology and precision oncology.

🧪 Experience

Dr. Frattini’s professional journey began in 1999 as a Research Fellow at the Consiglio Nazionale delle Ricerche in Milan, where he studied calcium-dependent protein kinases. From 2000 to 2005, he expanded his expertise in cancer biology as a Research Fellow at the Istituto Nazionale dei Tumori in Milan, focusing on experimental molecular pathology. Since 2005, he has been leading the Laboratory of Molecular Pathology at the Institute of Pathology in Locarno, Switzerland. In this role, he oversees advanced molecular diagnostic workflows, contributing directly to clinical decision-making. Since 2008, he has also managed the institute’s quality control systems, ensuring diagnostic accuracy and compliance with international standards. With extensive laboratory leadership and hands-on clinical experience, Dr. Frattini plays a key role in integrating molecular diagnostics into routine cancer care. His dual expertise in laboratory science and clinical pathology places him at the forefront of translational oncology research in Switzerland.

📈 Professional Development

Dr. Frattini has actively pursued professional development through editorial leadership, society memberships, and quality assurance roles. From 2010 to 2016, he served as Associate Editor of BMC Cancer, a prominent oncology journal. Since 2021, he has continued his editorial service with the Journal of Clinical Medicine, helping to guide scientific discourse in clinical research. He is a dedicated member of the Swiss Society of Pathology and the Swiss Group for Molecular Pathology, contributing to national standards in molecular diagnostics. Additionally, he participates in the SAKK Gastrointestinal and Lung Cancer Groups, which are instrumental in shaping Swiss clinical cancer trials. Dr. Frattini also holds the role of Head of Quality Control at his institute, ensuring laboratory processes meet stringent clinical and regulatory criteria. These roles demonstrate his commitment not only to research excellence but also to the development of best practices in molecular pathology, professional collaboration, and clinical innovation.

🔬 Research Focus

Dr. Frattini’s research focuses on the molecular characterization of solid tumors, with a particular emphasis on gastrointestinal and pulmonary cancers. His work aims to uncover the genomic and epigenetic alterations that drive tumor progression and treatment resistance. By integrating molecular profiling into diagnostic workflows, his research supports the personalization of cancer therapy. His Ph.D. work on small bowel adenocarcinoma—a rare and under-researched cancer—demonstrates his commitment to uncovering novel targets in hard-to-treat malignancies. He is also involved in studying molecular markers that predict patient response to targeted therapies and immunotherapies. Through collaborations with the SAKK groups, he contributes to clinical trial development and biomarker validation in real-world oncology settings. His translational research serves as a bridge between laboratory discoveries and bedside applications, significantly enhancing diagnostic precision and treatment outcomes in cancer care.

🧠 Research Skills

Dr. Frattini possesses a comprehensive skill set that spans molecular diagnostics, biomarker discovery, next-generation sequencing (NGS), and translational oncology. He is proficient in applying molecular biology techniques—such as PCR, DNA sequencing, and FISH—to clinical pathology. His leadership of a molecular pathology laboratory involves the integration of high-throughput genomic analysis with traditional histopathology, optimizing tumor profiling for patient-specific treatments. He has experience in validating diagnostic assays for clinical use, ensuring both analytical sensitivity and specificity. His research also includes skillful design and interpretation of retrospective and prospective molecular studies, which inform therapeutic decisions in gastrointestinal and lung cancers. Additionally, his editorial and review work reflect advanced skills in scientific evaluation, literature synthesis, and methodological rigor. Dr. Frattini’s ability to combine technical expertise, clinical understanding, and quality control makes him an asset to the fields of precision medicine and oncology diagnostics.

🏆 Awards and Honors

While specific named awards are not listed in the CV, Dr. Milo Frattini’s career reflects numerous professional honors and responsibilities that underline his recognition in the scientific community. His long-standing editorial roles with BMC Cancer and Journal of Clinical Medicine indicate a high level of peer respect and scientific credibility. Being appointed as Head of both the Molecular Pathology Laboratory and Quality Control Division at the Institute of Pathology in Locarno is a significant institutional acknowledgment of his leadership and expertise. Furthermore, his membership in elite professional bodies such as the Swiss Group for Molecular Pathology, the Swiss Society of Pathology, and SAKK oncology groups points to his continued professional trust and influence. These roles, though not formal awards, collectively highlight Dr. Frattini’s impact, reliability, and sustained excellence in cancer research and molecular diagnostics.

Publication Top Notes

1. Neo‑RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review

Citation: 2

Pesola, G., Epistolio, S., Cefalì, M., Trevisi, E., De Dosso, S., & Frattini, M. (2024). Neo‑RAS Wild Type or RAS Conversion in Metastatic Colorectal Cancer: A Comprehensive Narrative Review. Cancers, 16(23), 3923. https://doi.org/10.3390/cancers16233923 MDPIMDPIResearchGate

Summary:
This narrative review outlines the phenomenon of neo‑RAS wild‑type cancer, in which metastatic colorectal tumors originally harboring RAS mutations convert to wild‑type status during or after chemotherapy. The proposed mechanisms include selective depletion of RAS‑mutant clones and expansion of pre‑existing RAS wild‑type clones. The clinical implications concern eligibility for anti‑EGFR therapies in converted patients, with potential survival benefits. The review emphasizes the need for liquid biopsy monitoring, improved detection techniques, and further validation of outcomes such as progression‑free and overall survival Nature+7PubMed+7ResearchGate+7.

2. Biomarker Characterization in Endometrial Cancer in Europe: First Survey Data Analysis from 69 Pathological Academic and Hospital Labs

Citation: 6

Santoro, A., Bragantini, E., Castiglione, F., et al. (2024). Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs. Pathologica, 116(1), 32–45. https://doi.org/10.32074/1591‑951X‑926 PubMedPMC

Summary:
This multicentric observational study surveyed 69 European pathology labs (academic and hospital‐based) across Italy, Spain, Switzerland, and the UK regarding practices in molecular biomarker testing for endometrial cancer. It reports variability in the routine use of immunohistochemistry (e.g., MMR, p53) and molecular testing (such as POLE), highlighting heterogeneity in adoption. Barriers such as resource limitations and lack of standardization were noted, indicating a need for European‐wide guidelines and more uniform workflows PubliRES+5PMC+5ResearchGate+5.

3. Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis

Citation: 4

Clinical relevance and interplay between miRNAs in influencing glioblastoma multiforme prognosis (2025). CMBL (review article). MDPIPubMedMDPI

Summary:
This recent narrative/review article discusses how specific microRNAs modulate gene networks influential in glioblastoma multiforme (GBM) progression and patient prognosis. It stresses GBM’s dismal median survival (~12–15 months) and explores key miRNAs such as miR‑9 (oncogenic, associated with chemoresistance and poor survival), miR‑221/222 (promoting proliferation, angiogenesis), and tumor-suppressive miR‑181a/b. Emerging evidence around circulating miR‑29a, miR‑106a, and miR‑200a as prognostic markers is also highlighted. The article proposes miRNA profiles as potential biomarkers and therapeutic targets in GBM management Nature.

4. Antiandrogens as Therapies for COVID‑19: A Systematic Review

Citation: 3

(2023). Antiandrogens as Therapies for COVID‑19: A Systematic Review. Included original studies through August 2023. ResearchGatePMC

Summary:
This systematic review (covering March 2020 to August 2023) evaluates the evidence for antiandrogenic therapies—including androgen-deprivation therapy (ADT), 5‑alpha-reductase inhibitors, and antiandrogens like bicalutamide, enzalutamide, and proxalutamide—in improving COVID‑19 outcomes. Of 31 studies screened, results were mixed: proxalutamide showed potential in accelerating viral clearance and reducing hospitalizations in benign severity cases, but large-scale randomized data are lacking. Conversely, trials of enzalutamide and bicalutamide failed to show therapeutic benefit and raised safety signals—–bicalutamide is associated with increased mortality, particularly cardiovascular risk—suggesting antiandrogens are not broadly effective as COVID‑19 treatments ScienceDirect+4ResearchGate+4PMC+4.

🏁 Conclusion:

Dr. Milo Frattini exemplifies the qualities of an outstanding researcher—scientific excellence, translational impact, clinical relevance, and leadership. His contributions significantly advance molecular pathology and personalized cancer treatment. In the absence of formal international awards, his sustained academic, clinical, and editorial responsibilities clearly reflect peer recognition and influence. He is highly suitable and strongly recommended for the Best Researcher Award.